Key features contributing to the predictive value of the GBM included age, weight loss, Eastern Cooperative Oncology Group (ECOG) performance status, cancer biomarkers and serum markers of frailty, such as albumin and hemoglobin. This evidence concerns the gene ALB and glioblastoma.